Seres Therapeutics (MCRB)

• Market cap: $84.8M
• 1 day: 3.19%
• 5 days: 0.52%
• 1 month: -30.71%
• 3 months: -43.37%
• 6 months: -38.06%
• Year to date: -42.50%
• 1 year: -51.03%
• 5 years: -86.82%
• 10 years: -99.06%
• Sector: Healthcare
• Industry: Biotechnology

About: Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Employees: 103

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

860% more call options, than puts

Call options by funds: $2.76M | Put options by funds: $287K

6% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 17

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

4.66% less ownership

Funds ownership: 41.6% [Q3] → 36.94% (-4.66%) [Q4]

9% less funds holding

Funds holding: 76 [Q3] → 69 (-7) [Q4]

12% less capital invested

Capital invested by funds: $60M [Q3] → $52.5M (-$7.49M) [Q4]

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15 55% upside
• Avg. target: $20 106% upside
• High target: $25 158% upside

2 analyst ratings

• positive: 1 50%
• neutral: 0 0%
• negative: 1 50%

Chardan Capital Keay Nakae 18% 1-year accuracy 13 / 73 met price target	158% upside $25	Buy Maintained	20 Mar 2025
Goldman Sachs Chris Shibutani 25% 1-year accuracy 3 / 12 met price target	55% upside $15	Sell Maintained	14 Mar 2025